Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months) vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB) patients given BPaMZ for 26 Weeks (or 6 months)

Clinical Trial Description

Phase 2c multi-center, open-label, partially randomized clinical trial in DS-TB and DR-TB participants.

All participants in the below arms will have follow-up for a period of 104 weeks (24 months) from the start of therapy.

Participants with Drug Sensitive TB (DS-TB):

Participants with DS-TB will be randomized to one of two treatment arms. These participants will receive either BPaMZ daily for 17 weeks (4 months), or HRZE/HR combination tablets daily for 26 weeks (6 months). participants will be stratified for co-infection with human immunodeficiency virus (HIV) and cavitation.

Participants with Drug Resistant TB (DR-TB):

Participants with DR-TB will be assigned to receive BPaMZ daily for 26 weeks (6 months). ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03338621
Study type Interventional
Source Global Alliance for TB Drug Development
Contact Leandra Lombard
Phone 27833076784
Status Recruiting
Phase Phase 2
Start date July 30, 2018
Completion date January 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT03767946 - Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal
Recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Active, not recruiting NCT02273765 - Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis Phase 3
Completed NCT02536768 - Evaluation of South Africa's National Adherence Strategy N/A
Completed NCT02774993 - Doxycycline in Human Pulmonary Tuberculosis Phase 2
Terminated NCT02532036 - MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection Phase 1
Completed NCT02729571 - Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults Phase 1/Phase 2
Completed NCT01408914 - Trial of High-Dose Rifampin in Patients With TB Phase 2
Completed NCT01934309 - Do Clinical Decision-support Reminders for Medical Providers Improve the Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya? N/A
Completed NCT01450085 - Chepetsa TB - Reducing TB Among HIV-Infected Malawians N/A
Completed NCT01674218 - Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers Phase 1
Completed NCT01683773 - Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A Phase 1
Completed NCT02701439 - SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting N/A
Completed NCT01642888 - A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI Phase 3
Recruiting NCT01436929 - Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs N/A